Italia markets close in 1 hour 32 minutes

Exelixis, Inc. (0IJO.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
23,93+0,14 (+0,59%)
In data: 02:34PM GMT. Mercato aperto.

Exelixis, Inc.

1851 Harbor Bay Parkway
Alameda, CA 94502
United States
650 837 7000
https://www.exelixis.com

Settore/i
Settore
Impiegati a tempo pieno1.310

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Stelios Papadopoulos Ph.D.Co-Founder & Chair of the Board109kN/D1948
Dr. Michael M. Morrissey Ph.D.CEO, President & Director2,31MN/D1961
Mr. Christopher J. SennerExecutive VP & CFO1,09M2,93M1968
Mr. Jeffrey J. Hessekiel J.D.Executive VP, General Counsel & Secretary959,68kN/D1969
Mr. Patrick J. Haley M.B.A.Executive Vice President of Commercial844,64k1,76M1976
Dr. Dana T. Aftab Ph.D.Executive VP of Discovery and Translational Research & Chief Scientific OfficerN/DN/D1963
Ms. Susan T. HubbardExecutive Vice President of Public Affairs & Investor RelationsN/DN/DN/D
Ms. Laura DillardExecutive Vice President of Human ResourcesN/DN/DN/D
Dr. Peter Lamb Ph.D.Executive VP of Scientific Strategy909,46k10,72M1961
Dr. Anne Champsaur M.D.Senior Vice President of Drug SafetyN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Governance aziendale

L'ISS Governance QualityScore di Exelixis, Inc. al 1 marzo 2024 è 3. I criteri di valutazione fondamentali sono revisione: 5; Consiglio di Amministrazione: 2; diritti degli azionisti: 4; retribuzione: 4.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.